We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Masspec Pen Evaluated for Rapid Diagnosis of Cancer

By LabMedica International staff writers
Posted on 20 Jun 2019
Print article
The handheld MasSpec Pen device which can be connected to a Mass Spectrometer for diagnosing ovarian and other cancers (Photo courtesy of the University of Texas at Austin).
The handheld MasSpec Pen device which can be connected to a Mass Spectrometer for diagnosing ovarian and other cancers (Photo courtesy of the University of Texas at Austin).
Ovarian cancer is a highly lethal disease and the fifth leading cause of all cancer-related deaths in women. Accurate diagnosis and stratification of ovarian cancer is important to develop personalized treatment approaches.

Current methods for intraoperative tissue evaluation can be time intensive and subjective. A handheld and biocompatible device coupled to a mass spectrometer, has been developed, which uses a discrete water droplet for molecular extraction and rapid tissue diagnosis.

Scientists at The University of Texas at Austin (Austin, TX, USA) used the devise called the MasSpec Pen to analyze its performance on 192 ovarian, fallopian tube, and peritoneum tissue samples. The analyzed area of the tissue was demarcated and registered through optical images. Demarcated tissue or a parallel piece was frozen and sectioned at 10–16 μm using a CryoStar NX50 cryostat (Thermo Fisher Scientific, Waltham MA, USA), stained by standard hematoxylin and eosin procedure, and evaluated by expert pathologists to confirm diagnosis of the analyzed area. Performance using an Orbitrap and a linear ion trap mass spectrometer was tested. Of note, the final diagnoses were performed after MasSpec Pen analyses. Only 164 samples with clear diagnosis were used for statistical analysis.

The team reported that a high performance for 131 high-grade serous carcinoma (clinical sensitivity, 96.7%; specificity, 95.7%) and 138 overall cancer (clinical sensitivity, 94.0%; specificity, 94.4%) diagnoses was achieved using Orbitrap data. Discrimination between cancer and fallopian tube or peritoneum tissues was also achieved with accuracies of 92.6% and 87.9%, respectively, and 100% clinical specificity for both. Using ion trap data, excellent results for high-grade serous cancer versus normal ovarian differentiation were achieved.

The authors concluded that the MasSpec Pen, together with machine learning, provides robust molecular models for ovarian serous cancer prediction and thus has potential for clinical use for rapid and accurate ovarian cancer diagnosis. The study was published in the May 2019 issue of the journal Clinical Chemistry.

Related Links:
The University of Texas at Austin
Thermo Fisher Scientific


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.